Vazyme(SH:688105)2024-04-17 07:58Revenue Expectations - The company expects Q1 2024 revenue to be between 30,000 and 31,500 million CNY, representing a year-over-year increase of -0.7% to 4% compared to the same period last year[2]. - The company anticipates a narrowed loss in net profit attributable to the parent company, projected between -1,670 and -1,570 million CNY for Q1 2024, compared to the previous year[2]. - The projected share-based payment expenses for Q1 2024 are approximately 2,067 million CNY[2]. Profitability - The net profit attributable to the parent company for Q1 2024 is projected to be between 450 and 550 million CNY, marking a significant increase of 5,512 to 5,612 million CNY, or 109% to 111% year-over-year, indicating a turnaround from loss to profit[3]. - The company reported a net profit of -5,062 million CNY in Q1 2023, with a net profit excluding non-recurring gains and losses of -7,513 million CNY[4]. Operational Efficiency - Cost control measures have been effective, contributing to improved operational efficiency and reduced fixed costs during the reporting period[5]. - The company achieved significant growth in sales revenue due to the expansion of its life sciences product lines and improved sales systems, leading to a notable increase in international business revenue[5]. Market Development - The company continues to enhance its market presence through the commercialization of respiratory pathogen detection projects and the development of new pharmaceutical products[5]. Financial Forecast Integrity - The company emphasizes that the financial data in the earnings forecast is unaudited and subject to change upon the official Q1 2024 report[6]. - The company has not identified any significant uncertainties that could affect the accuracy of the earnings forecast[6].